Nocturne Acquisition Corporation (MBTCU)

SANTA ANA, CA / ACCESSWIRE / April 17, 2024 / Nocturne Acquisition Corp. (NASDAQ:MBTCU) (the "Company"), announced today that it will be unable to complete an initial business combination with Cognos Therapeutics, Inc. and intends to liquidate the Trust Account. In connection with the liquidation of the Trust Account, the Company will redeem all of the outstanding public shares of common stock (the "Public Shares") at a per-share redemption price of approximately $11.79, after taking into account the removal of a portion of the accrued interest in the Trust Account to pay taxes and dissolution expenses.

SANTA ANA, CA / ACCESSWIRE / March 19, 2024 / Nocturne Acquisition Corp. (NASDAQ:MBTCU) (the "Company"), announced today that the Board of Directors has voted in favor of postponing the meeting date for the Extraordinary General Meeting that was to be held on March 19, 2024 for shareholders to vote on the proposed business combination with Cognos Therapeutics, Inc. ("Cognos"). The Extraordinary General Meeting will now be held virtually on April 2, 2024 at 9:00 a.m.

SANTA ANA, CA / ACCESSWIRE / February 27, 2024 / Nocturne Acquisition Corp. (NASDAQ:MBTCU) (the "Company"), announced today that the Board of Directors has voted in favor of postponing the meeting date for the Extraordinary General Meeting that was to be held on February 27, 2024 for shareholders to vote on the proposed business combination with Cognos Therapeutics, Inc. ("Cognos"). The Extraordinary General Meeting will now be held virtually on March 19, 2024 at 9:00 a.m.

SANTA ANA, CA / ACCESSWIRE / February 5, 2024 / Nocturne Acquisition Corp. (NASDAQ:MBTCU) (the "Company"), announced today that the Board of Directors has voted in favor of a second postponement of the meeting date for the Extraordinary General Meeting that was to be held on January 30, 2024 for shareholders to vote on the proposed business combination with Cognos Therapeutics, Inc. The Extraordinary General Meeting that was postponed until February 6, 2024 has been postponed further and will now be held virtually on February 27, 2024 at 9:00 a.m. Eastern Time.

SANTA ANA, CA / ACCESSWIRE / January 30, 2024 / Nocturne Acquisition Corp. (NASDAQ:MBTCU) (the "Company"), announced today that the Board of Directors has voted in favor of postponing the meeting date for the Extraordinary General Meeting that was to be held on January 30, 2024 for shareholders to vote on the proposed business combination with Cognos Therapeutics, Inc. The Extraordinary General Meeting will now be held virtually on February 6, 2024 at 10:00 a.m. Eastern Time, and the Company plans to continue to solicit proxies from shareholders during the period prior to the Extraordinary General Meeting.

Transaction Expected to Accelerate the Research and Advancement of Cognos' Proprietary and Innovative Implantable Drug Delivery Pump to Improve Outcomes for Treatment of Brain Cancers and Other Neurological Diseases WILMINGTON, DE / ACCESSWIRE / August 16, 2023 / Nocturne Acquisition Corporation (NASDAQ:MBTC)(NASDAQ:MBTCU)(NASDAQ:MBTCR) (the "Company", "MBTC" or "Nocturne"), today announced the submission via Edgar, the U.S. Securities and Exchange Commission's ("SEC") online portal, for filing of a registration statement on Form S-4 (the "Registration Statement") with the SEC, which includes a preliminary proxy statement/prospectus in connection with the proposed business combination (the "Business Combination") with Cognos Therapeutics, Inc. ("Cognos"), a medical technology company focused on developing unique, radically advanced devices for the treatment of neurological diseases including brain and spinal cancers, and degenerative neurological conditions (such as Alzheimer's and Parkinson's disease), epilepsy, and stroke. The Registration Statement contains a preliminary proxy statement/prospectus in connection with the previously announced Business Combination between Nocturne and Cognos.

LA JOLLA, CA / ACCESSWIRE / June 4, 2021 / Nocturne Acquisition Corporation (NASDAQ:MBTCU) (the "Company") today announced that it has received a notice ("Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the "Form 10-Q") in a timely fashion. The Notice advised the Company that it was not in compliance with Nasdaq's continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1).

LA JOLLA, CA / ACCESSWIRE / April 29, 2021 / Nocturne Acquisition Corporation (NASDAQ:MBTCU) (the "Company" or "MBTC") announced that, commencing May 3, 2021, holders of the units sold in the Company's initial public offering of 11,500,000 units, may elect to separately trade shares of the Company's ordinary shares and rights included in the units. The ordinary shares and rights that are separated will trade on the Nasdaq Capital Market under the symbols "MBTC" and "MBTCR," respectively.

LA JOLLA, CA / ACCESSWIRE / April 14, 2021 / Nocturne Acquisition Corporation (NASDAQ:MBTCU), the "Company") announced today that the underwriters in its initial public offering, pursuant to the terms of the underwriting agreement, fully exercised their over-allotment option and, on April 14, 2021, closed the purchase of an additional 1,500,000 units in connection with its initial public offering at $10.00 per unit, generating additional gross proceeds of $15,000,000 and bringing the total gross proceeds of the initial public offering to $115,000,000. Each unit consists of one ordinary share and one right to receive one-tenth of one ordinary share upon the consummation of an initial business combination.